Provided by Tiger Trade Technology Pte. Ltd.

Prothena Corp PLC

9.82
+0.22002.29%
Post-market: 9.75-0.0700-0.71%19:30 EDT
Volume:383.93K
Turnover:3.75M
Market Cap:504.13M
PE:-11.78
High:9.87
Open:9.50
Low:9.48
Close:9.60
52wk High:11.80
52wk Low:7.73
Shares:51.34M
Float Shares:40.12M
Volume Ratio:1.12
T/O Rate:0.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8337
EPS(LYR):-4.5346
ROE:-14.39%
ROA:-10.67%
PB:1.76
PE(LYR):-2.17

Loading ...

Press Release: Prothena to Report First Quarter 2026 Financial Results on May 7

Dow Jones
·
May 01

Prothena to report first-quarter results after U.S. market close

Reuters
·
May 01

Prothena says FDA grants Fast Track designation to Novo Nordisk’s coramitug PRX004 for ATTR-CM

Reuters
·
Apr 28

Prothena Corporation Plc - Coramitug Phase 3 Cleopattra Trial Enrolls ~1,280 Participants; Primary Completion Expected in 2029

THOMSON REUTERS
·
Apr 28

Prothena Announces Novo Nordisk Obtains Fast Track Designation From the U.S. FDA for Coramitug (Prx004) in Attr Amyloidosis With Cardiomyopathy

THOMSON REUTERS
·
Apr 28

Prothena files Form 3 for Chief Strategy Officer Anne Evans Kingston

Reuters
·
Apr 11

Prothena promotes Annie Kingston to chief strategy officer amid legal chief transition

Reuters
·
Apr 11

Prothena Announces Leadership Team Updates

THOMSON REUTERS
·
Apr 11

Prothena announced its annual general meeting of shareholders

Reuters
·
Mar 28

Prothena partners present prasinezumab and BMS-986446 clinical study updates at AD/PD 2026

Reuters
·
Mar 22

Prothena Corporation plc publishes corporate overview presentation on protein dysregulation disease pipeline and USD 308.4 million cash position

Reuters
·
Mar 10

Prothena achieves $50M clinical milestone payment from Novo Nordisk

TIPRANKS
·
Mar 10

Prothena earns USD 50 million milestone payment from Novo Nordisk

Reuters
·
Mar 10

Prothena Announces Achievement of $50 Million Clinical Milestone Payment From Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly Prx004) in Attr Amyloidosis With Cardiomyopathy

THOMSON REUTERS
·
Mar 10

Prothena Corporation Plc - Novo Nordisk Phase 3 Coramitug Trial in Attr-Cm Expected to Complete in 2029

THOMSON REUTERS
·
Mar 10